J9349 HCPCS code: Injection, tafasitamab-cxix, 2 mg
J9349 is the HCPCS Level II code for injection, tafasitamab-cxix, 2 mg. In 2024 Medicare paid an average of $10.52 per service for J9349 across 1,215,326 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 900 per day on outpatient hospital claims. Medicare volume fell 18% from 2022 to 2024 (1,481,832 to 1,215,326 services). In 2024, about 458 clinicians billed Medicare for J9349 for 209 beneficiaries; Texas, Florida, California accounted for 76% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2021-04-01 |
| Last action effective | 2021-04-01 |
Who bills J9349 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 458 |
| Medicare beneficiaries | 209 |
| States with claims | 6 |
| Share of services in top 3 states (Texas, Florida, California) | 76% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9349, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 1,481,832 | 275 | $12.72 | $10.16 |
| 2023 | 1,343,047 | 235 | $12.96 | $10.32 |
| 2024 | 1,215,326 | 209 | $13.21 | $10.52 |
States with the most J9349 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 202,010 | $10.71 |
| Florida | 171,889 | $10.72 |
| California | 165,382 | $10.69 |
| Arizona | 70,900 | $10.71 |
| New York | 50,279 | $10.70 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 900 | Prescribing Information |
| practitioner claims | 900 | Prescribing Information |
What changed for J9349
- 2021-04-01: J9349 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9349?
J9349 is the HCPCS Level II code for injection, tafasitamab-cxix, 2 mg. Short descriptor: "Inj., tafasitamab-cxix".
How much does Medicare pay for J9349?
In 2024, the average Medicare payment was $10.52 per service (average allowed $13.21).
Does Medicare cover J9349?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9349 can be billed per day?
900 on outpatient hospital claims; 900 on practitioner claims (NCCI medically unlikely edits).
Related J93 codes
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9309 — Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9349
- Watch J9349 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9349
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.